Some cancer mutations gave rise to neoantigens that were immunogenic for both CD8+ and CD4+ T cells and were recognized in the context of several different restriction elements, showing that concurrent TCR- and phenotype-diverse immune responses can be mounted against a single cancer mutation. Here, CD4 is linked to cancer.